SVR12 in combination of bemnifosbuvir and ruzasvir - (C-BEYOND)

July 28, 2026: Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) reported positive topline results from C-BEYOND, a pivotal Phase 3 North America trial comparing once-daily fixed-dose bemnifosbuvir/ruzasvir (BEM/RZR) vs sofosbuvir/velpatasvir (SOF/VEL; Epclusa) for chronic hepatitis C (HCV). In the modified intent-to-treat population (n=905; cirrhotic and non-cirrhotic), BEM/RZR achieved the primary endpoint of statistical non-inferiority with SVR 93.9% vs 94.8% for SOF/VEL at Week 24 (encompassing SVR12), with the 95% CI for the difference within the prespecified 5% margin.

By subgroup: non-cirrhotic (n=721), BEM/RZR for 8 weeks achieved SVR 93.5% vs 94.6% for SOF/VEL (12 weeks); cirrhotic (n=184; both 12 weeks), SVR was 95.4% in both arms. Virologic failure rates were low and comparable; secondary endpoints including per-protocol non-inferiority were met. BEM/RZR was generally safe and well tolerated with no drug-related serious AEs or drug-related early discontinuations.

Upcoming catalyst: C-FORWARD (global ex–North America Phase 3; >880 enrolled) topline results expected in early 2027; Atea plans future conference presentations and journal publication submissions.